Key Opinion Leaders Highlight MDxHealth’s Commercial Portfolio
IRVINE, CA, and HERSTAL, BELGIUM – June 14, 2016 – MDxHealth SA (Euronext: MDXH.BR), announced that a replay of its Capital Markets Day presentation, held earlier today in New York City, is currently available. During the event, management provided an overview of company operations, including the commercial status of its ConfirmMDx® and SelectMDx(TM) tests for prostate cancer and an R&D review that highlighted AssureMDx(TM) for bladder cancer. No new information was reported.
Guest speakers included E. David Crawford, MD, Head of Urologic Oncology at the University of Colorado Denver (UCD), and Neal Shore, MD, Director CPI, Carolina Urologic Research Center, Myrtle Beach, South Carolina.
An event webcast replay is now available at the MDxHealth investor website at www.mdxhealth.com/investors.
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company’s tests are based on proprietary gene methylation (epigenetic) and other molecular technologies and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.
| For more information: Dr. Jan Groen, CEO MDxHealth US: +1 949 812 6979 BE: +32 4 364 20 70 info@mdxhealth.com |
Consilium Strategic Communications Amber Fennell, Chris Welsh & Hendrik Thys UK: +44 20 3709 5701 mdxhealth@consilium-comms.com |
|
| Rx Communications Group, LLC Melody Carey, Steve Silver US: 917-322-2571/917-322-2569 mdxhealth@rxir.com |
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx and AssureMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.
